Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lucid Diagnostics (LUCD) EBITDA (2022 - 2025)

Historic EBITDA for Lucid Diagnostics (LUCD) over the last 4 years, with Q3 2025 value amounting to -$11.8 million.

  • Lucid Diagnostics' EBITDA fell 55.58% to -$11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.0 million, marking a year-over-year decrease of 636.81%. This contributed to the annual value of -$46.1 million for FY2024, which is 501.22% up from last year.
  • Lucid Diagnostics' EBITDA amounted to -$11.8 million in Q3 2025, which was down 55.58% from -$11.4 million recorded in Q2 2025.
  • Lucid Diagnostics' EBITDA's 5-year high stood at -$10.8 million during Q1 2024, with a 5-year trough of -$15.0 million in Q4 2022.
  • For the 4-year period, Lucid Diagnostics' EBITDA averaged around -$12.4 million, with its median value being -$11.8 million (2025).
  • As far as peak fluctuations go, Lucid Diagnostics' EBITDA plummeted by 1667.35% in 2023, and later surged by 2462.11% in 2024.
  • Over the past 4 years, Lucid Diagnostics' EBITDA (Quarter) stood at -$15.0 million in 2022, then rose by 23.52% to -$11.5 million in 2023, then dropped by 8.05% to -$12.4 million in 2024, then increased by 4.98% to -$11.8 million in 2025.
  • Its last three reported values are -$11.8 million in Q3 2025, -$11.4 million for Q2 2025, and -$12.5 million during Q1 2025.